Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$805.20 USD

805.20
2,092,822

-0.94 (-0.12%)

Updated Nov 5, 2024 02:17 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nilanjan Banerjee headshot

5 Low-Beta Stocks to Beat Coronavirus-Induced Volatility

by Nilanjan Banerjee

To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $163.88 in the latest trading session, marking a +1.11% move from the prior day.

FDA Grants Extra Access to Vanda's Tradipitant to a Patient

by Zacks Equity Research

Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.

Ritujay Ghosh headshot

FDA Aims to Fast-Track Coronavirus Vaccine: 3 Stocks in Focus

by Ritujay Ghosh

Vaccine seems to be the only hope now to counter the pandemic given that millions of new cases of coronavirus are being reported every day.

Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (LLY) Outperforming Other Medical Stocks This Year?

Bayer's Drug Meets Primary Endpoint in Renal Outcomes Study

by Zacks Equity Research

Bayer's (BAYRY) investigational candidate, finerenone, meets primary endpoint in the phase III FIDELIO_DKD study in patients with CKD and T2D.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, AZN Regulatory Updates, GSK's New Coronavirus Deal

by Kinjel Shah

Merck (MRK) and AstraZeneca (AZN) provide updates on regulatory applications related to key drugs

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $169.13, moving +1.43% from the previous trading session.

Regeneron Initiates Studies on Experimental Coronavirus Drug

by Zacks Equity Research

Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.

Here's Why Lilly (LLY) Stock is Up Despite Coronavirus Crisis

by Zacks Equity Research

Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make medicines/antibodies to treat COVID-19.

Ritujay Ghosh headshot

4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine

by Ritujay Ghosh

The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.

Benjamin Rains headshot

3 Diverse Stocks to Buy Now for Second Half Coronavirus Immunity & Growth

by Benjamin Rains

A look at three stocks from completely different economic sectors that are poised to grow during the second half of 2020, despite continued coronavirus economic uncertainty...

The Zacks Analyst Blog Highlights: Tesla, NVIDIA, Amazon.com, T-Mobile US and Eli Lilly

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Tesla, NVIDIA, Amazon.com, T-Mobile US and Eli Lilly

4 Reasons to Own AbbVie Stock as Coronavirus Woes Linger

by Zacks Equity Research

AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.

Johnson & Johnson Gets European Approval for Ebola Vaccine

by Zacks Equity Research

J&J (JNJ) gets approval from the European Commission for Ebola vaccine.

Nalak Das headshot

Pandemic Fails to Deter YTD Rally of These Top 5 US Behemoths

by Nalak Das

A handful of corporate behemoths has skyrocketed YTD. Some of these stocks carry a favorable Zacks Rank and have rallied more than 20% YTD.

Benjamin Rains headshot

Buy Pharma Giant AbbVie Stock for Growth, Income & Coronavirus Safety

by Benjamin Rains

All of this might make investors want to consider AbbVie for the second half of 2020 with coronavirus fears and volatility likely to linger...

The Zacks Analyst Blog Highlights: Visa, JPMorgan Chase, Bank of America, Chevron and Eli Lilly

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Visa, JPMorgan Chase, Bank of America, Chevron and Eli Lilly

Benjamin Rains headshot

3 Dividend Stocks to Buy for Second Half of 2020 for Coronavirus Safety

by Benjamin Rains

Check out these three stocks with solid dividend yields that appear ready to continue to weather the coronavirus economic downturn in the second half of 2020...

Sheraz Mian headshot

Top Analyst Reports for Visa, JPMorgan & Bank of America

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Visa (V), JPMorgan Chase (JPM) and Bank of America (BAC).

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Eli Lilly (LLY) closed at $162.72, marking a -0.07% move from the previous day.

Novartis Gets Positive CHMP View for Cosentyx Label Expansion

by Zacks Equity Research

Novartis' (NVS) Cosentyx gets positive CHMP opinion for moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years.

J&J (JNJ) Discontinues Phase III Study of Stelara for Lupus

by Zacks Equity Research

Johnson & Johnson (JNJ) discontinues phase III study of Stelara (ustekinumab) in systemic lupus erythematosus.

Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (LLY) Outperforming Other Medical Stocks This Year?